Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.
Journal: The Journal of infectious diseases
Published: November 19, 2024
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics.
Journal: Gut microbes
Published: September 18, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Journal: Infectious diseases and therapy
Published: August 30, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Journal: Infectious diseases and therapy
Published: February 27, 2024
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.
Journal: Nature medicine
Published: September 18, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 16, 2023
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
Journal: The Journal of infectious diseases
Published: June 06, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 14, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
Journal: JAMA network open
Published: February 13, 2023
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA network open
Published: January 30, 2023
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
Journal: JAMA
Published: October 19, 2022
Last Updated: 09/26/2026